Please provide your email address to receive an email when new articles are posted on . The American Association for the Study of Liver Diseases Foundation has granted $3.42 million in research and ...

DURHAM, N.C., March 18, 2025 /PRNewswire/ -- The American Association for the Study of Liver Diseases (AASLD) is inviting members to apply as site principal investigators to participate in TARGET-LD, ...

The American Association for the Study of Liver Diseases (AASLD) has revised its metabolic dysfunction-associated steatotic liver disease (MASLD) practice guidelines to include semaglutide for ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 16, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving ...

At the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases (AASLD), a highlight came during the President's Choice Lecture, where former NIH director Francis ...

New research and updated guidelines highlight the urgent need to standardize noninvasive liver fibrosis screening as metabolic dysfunction-associated steatotic liver disease (MASLD) cases climb ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The American Association for the Study of Liver Diseases ...

Editor's Note: Choosing Wisely®, an initiative of the American Board of Internal Medicine (ABIM) Foundation, comprises evidence-based recommendations from specialty organizations on commonly used ...

A late afternoon talk on the third day at The Liver Meeting 2014, evaluated the influence of some of the newer antiviral agents on "brain fog," a phenomenon quite commonly observed in hepatitis C ...

-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company’s interferon-α receptor agonist program -- At the meeting, one poster presentation ...

At the annual Liver Meeting sponsored by the American Association for the Study of Liver Diseases (AASLD), AASLD President Grace L. Su, MD, of the University of Michigan in Ann Arbor, highlighted ...

Atea Pharmaceuticals (AVIR) announced it presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus, or HCV. The ...